IS SERUM CA-125 AT THE TIME OF RELAPSE A PROGNOSTIC INDICATOR FOR FURTHER SURVIVAL PROGNOSIS IN PATIENTS WITH OVARIAN-CANCER

被引:25
作者
MAKAR, AP
KRISTENSEN, GB
BORMER, OP
TROPE, CG
机构
[1] NORWEGIAN RADIUM HOSP,DEPT GYNECOL ONCOL,N-0310 OSLO,NORWAY
[2] NORWEGIAN RADIUM HOSP,CENT LAB,N-0310 OSLO,NORWAY
关键词
D O I
10.1006/gyno.1993.1076
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The prognostic significance of serum CA 125 level before treatment of relapse for invasive epithelial ovarian cancer has been evaluated in 135 patients. At time of relapse, serum CA 125 level was higher than 35 U/ml in 110 (82%) patients. Those with serum CA 125 level of 35 U/ml or less at relapse had a better prognosis than those with higher values. Among patients with serum CA 125 level higher than 35 U/ml no difference in survival was observed. By multivariate analysis the independent prognostic factors for survival were histologic type (P < 0.0001) and serum CA 125 level (P < 0.01). Randomized trials are needed to further evaluate whether early detection of disease relapse because of serial serum CA 125 measurements does have prognostic significance. © 1993 Academic Press, Inc.
引用
收藏
页码:3 / 7
页数:5
相关论文
共 16 条
[1]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[2]   SERUM CA-125 IN EPITHELIAL OVARIAN-CANCER - A LONGITUDINAL-STUDY [J].
BRIOSCHI, PA ;
IRION, O ;
BISCHOF, P ;
BADER, M ;
FORNI, M ;
KRAUER, F .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1987, 94 (03) :196-201
[3]  
BRUZZONE M, 1990, ANTICANCER RES, V10, P1353
[4]  
COLDMAN AJ, 1979, CAN MED ASSOC J, V121, P1065
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]  
CROMBACH G, 1985, CANCER DETECT PREV, V8, P135
[7]   LONG-TERM FOLLOW-UP OF OVARIAN-CANCER WITH MONTHLY DETERMINATIONS OF SERUM CA-125 [J].
HOGBERG, T ;
KAGEDAL, B .
GYNECOLOGIC ONCOLOGY, 1992, 46 (02) :191-198
[8]  
JACOBS I, 1989, HUM REPROD, V4, P1
[9]   SERUM CA-125 AS A GUIDELINE FOR THE TIMING OF A 2ND-LOOK OPERATION AND 2ND-LINE TREATMENT IN OVARIAN-CANCER [J].
JAGER, W ;
ADAM, R ;
WILDT, L ;
LANG, N .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1988, 243 (02) :91-99
[10]  
KREBS HB, 1986, OBSTET GYNECOL, V67, P473